Current treatment for anorexia nervosa: efficacy, safety, and adherence by Bodell, Lindsay P & Keel, Pamela K
© 2010 Bodell and Keel, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Psychology Research and Behavior Management 2010:3 91–108
Psychology Research and Behavior Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
91
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/PRBM.S13814
Current treatment for anorexia nervosa: efficacy, 
safety, and adherence
Lindsay P Bodell
Pamela K Keel
Department of Psychology, Florida 
State University, Tallahassee, FL, USA
Correspondence: Lindsay P Bodell
1107 west Call Street, Tallahassee,  
FL 32306, USA
Tel +1 850 645 9141
email bodell@psy.fsu.edu
Abstract: Anorexia nervosa (AN) is a serious psychiatric illness associated with significant 
medical and psychiatric morbidity, psychosocial impairment, increased risk of death, and 
  chronicity. Given the severity of the disorder, the establishment of safe and effective treatments 
is necessary. Several treatments have been tried in AN, but few favorable results have emerged. 
This paper reviews randomized controlled trials in AN, and provides a synthesis of existing data 
regarding the efficacy, safety, and adherence associated with pharmacologic and psychological 
interventions. Randomized controlled trials for the treatment of AN published in peer-reviewed 
journals were identified by electronic and manual searches. Overall, pharmacotherapy has   limited 
benefits in the treatment of AN, with some promising preliminary findings associated with 
olanzapine, an antipsychotic agent. No single psychological intervention has demonstrated clear 
superiority in treating adults with AN. In adolescents with AN, the evidence base is strongest for 
the use of family therapy over alternative individual psychotherapies. Results highlight   challenges 
in both treating individuals with AN and in studying the effects of those treatments, and further 
emphasize the importance of continued efforts to develop novel interventions.   Treatment trials 
currently underway and areas for future research are discussed.
Keywords: anorexia nervosa, treatment, pharmacotherapy, psychotherapy, randomized 
  controlled trials
Introduction
Anorexia nervosa (AN) is a serious psychiatric illness defined in the Diagnostic and 
Statistical Manual for Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) 
as a refusal to maintain minimally normal body weight, an intense fear of gaining 
weight or becoming fat, cognitive disturbances regarding one’s body weight and 
shape, and amenorrhea in postmenarcheal females.1 AN has been associated with one 
of the highest rates of mortality among all psychiatric disorders,2 due to both medical 
complications and suicide.3 Given the severity of AN, the establishment of both safe 
and effective treatments for the disorder is imperative.
Pharmacologic and psychological treatments for AN have been designed to target 
the core features that define AN (weight, appetite, distorted thoughts, and behaviors) 
as well as secondary symptoms, such as depression and anxiety. Although a variety 
of treatments have been tried for AN, few randomized controlled trials (RCTs) have 
been conducted, and few favorable results have emerged. The aim of this paper is to 
review RCTs in AN to summarize the efficacy, safety, and adherence associated with 
current treatments for AN.Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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Methods
Treatment trials were identified by electronic searches of 
the PubMed and PsychINFO databases from 1980 to May 
2010 using the search terms “anorexia nervosa”, “treatment”, 
“pharmacology”, “medication”, “antidepressants”, “antipsy-
chotics”, “psychotherapy”, “cognitive behavioral therapy”, 
“family therapy”, “inpatient”, and “hospitalization”. Given 
the current review’s focus on efficacy, nonrandomized, non-
controlled treatment trials were excluded following review 
of abstracts and when necessary, the articles. The reference 
sections of all articles were reviewed to identify additional 
studies.
Information regarding treatment conditions, length of 
treatment, sample size, proportion of female participants, 
treatment adherence, treatment outcome, and side effects or 
adverse outcomes were obtained from all articles (n = 33) that 
met the inclusion criteria. Table 1 summarizes the information 
for pharmacotherapy trials, Table 2 for psychotherapy trials, 
and Table 3 for trials comparing inpatient and outpatient 
treatment programs. No studies compared the efficacy 
of pharmacotherapy to psychotherapy, and studies that 
examined the efficacy of medications added to psychotherapy 
are included in Table 1.
Results
Medication trials
Several classes of medication have been examined in the 
treatment of AN. Evidence regarding the efficacy of phar-
macotherapy for AN is limited, and there are currently no 
medications for the treatment of AN that are approved by 
the US Food and Drug Administration.
Antidepressants
The most prominently studied drug class for AN is antide-
pressants. Antidepressants have shown efficacy in the treat-
ment of several Axis I disorders including major depression, 
obsessive compulsive disorder, and bulimia nervosa (BN). 
Based on shared features between AN and disorders that 
respond favorably to treatment with antidepressants, different 
classes of antidepressants, including tricyclics (TCAs) and 
selective serotonin reuptake inhibitors (SSRIs), have been 
evaluated in the treatment of AN.
Efficacy
Early antidepressant medication trials evaluated TCAs, includ-
ing clomipramine and amitriptyline. In general, the TCAs 
have not proven to be effective in treating the core symp-
toms of AN or concurrent depression. Two RCTs evaluating 
the impact of clomipramine (a serotonin, norepinephrine, 
and dopamine blocker) as adjunctive treatment to inpatient 
hospitalization4,5 found no benefits of this   medication on 
weight gain or any psychological symptoms compared with 
placebo, amisulpride (an antipsychotic), or fluoxetine (an 
SSRI). Amitriptyline, a serotonin-norepinephrine reuptake 
inhibitor, has also been evaluated as adjunctive treatment to 
inpatient hospitalization,6 as well as in an outpatient trial.7 
In a five-week outpatient trial, amitriptyline was no more 
effective than either placebo or a no-drug comparison group 
in the treatment of AN or associated depressive symptoms.7 
Similarly, compared with the antiserotonergic agent cypro-
heptadine, amitriptyline showed no improvements on weight 
gain or psychological symptoms beyond that of inpatient 
hospitalization.6 However, cyproheptadine was associated 
with decreased depression compared with placebo and an 
increased rate of weight gain and caloric intake in   restricting 
AN patients. This benefit was offset by cyproheptadine’s 
decreased treatment efficiency (defined as the reciprocal 
of days to target weight times the maximum possible days 
of hospitalization) in bulimic AN patients compared with 
amitriptyline and placebo.
SSRIs have been evaluated in both the acute and 
maintenance treatment phases of AN. Despite its benefi-
cial effects in other disorders, fluoxetine does not appear 
efficacious in the treatment of AN in underweight8 or 
weight-restored9 individuals. Two RCTs have evaluated 
the effectiveness of fluoxetine in preventing relapse in 
recently weight-restored women with AN up to one year 
following hospitalization.9,10 Kaye et al10 initially found 
fluoxetine to be associated with improvements in weight, 
depression, anxiety, obsessions and compulsions, and core 
eating disorder (ED)   symptoms from baseline to the end of 
the study. However, only three individuals (15%) from the 
placebo group remained on treatment after one year, thus 
limiting comparisons between the two groups. In contrast, 
in a larger multisite trial of fluoxetine versus placebo in 
weight-restored women receiving outpatient cognitive 
behavioral therapy (CBT), Walsh et al9 found no differ-
ences between fluoxetine and placebo in time to relapse, 
  percentage of patients maintaining a body mass index of at 
least 18.5 kg/m2, or percentage of patients meeting criteria 
for at least a fair outcome. Additionally, there were no dif-
ferences between fluoxetine and placebo on the secondary 
outcome measures of depression, core ED symptoms, and 
quality of life. However, there was a beneficial effect of flu-
oxetine on anxiety. Given its greater methodologic strengths, 
the Walsh et al9 study likely represents a more accurate Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
93
Current treatment for anorexia nervosa
T
a
b
l
e
 
1
 
R
a
n
d
o
m
i
z
e
d
 
c
o
n
t
r
o
l
l
e
d
 
m
e
d
i
c
a
t
i
o
n
 
t
r
i
a
l
s
 
i
n
 
a
n
o
r
e
x
i
a
 
n
e
r
v
o
s
a
R
e
f
e
r
e
n
c
e
n
S
e
x
 
 
(
%
 
F
)
A
g
e
,
 
y
e
a
r
s
 
 
(
m
e
d
i
a
n
)
I
n
c
l
u
s
i
o
n
 
 
c
r
i
t
e
r
i
a
E
x
c
l
u
s
i
o
n
 
 
c
r
i
t
e
r
i
a
T
r
e
a
t
m
e
n
t
 
 
c
o
n
d
i
t
i
o
n
s
T
r
e
a
t
m
e
n
t
 
 
c
o
m
p
l
e
t
i
o
n
O
u
t
c
o
m
e
 
 
m
e
a
s
u
r
e
s
R
e
s
u
l
t
s
 
 
s
u
m
m
a
r
y
*
*
T
r
i
c
y
c
l
i
c
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
L
a
c
e
y
 
a
n
d
 
C
r
i
s
p
4
1
6
1
0
0
–
A
N
–
∼
1
1
 
w
e
e
k
s
 
5
0
 
m
g
/
d
a
y
 
 
C
L
O
 
(
8
)
 
v
e
r
s
u
s
 
P
L
A
 
(
8
)
C
L
O
 
6
 
(
7
5
%
)
 
 
P
L
A
 
7
 
(
8
8
%
)
M
e
a
n
 
w
T
 
g
a
i
n
 
 
R
a
t
e
 
o
f
 
w
T
 
g
a
i
n
 
 
v
A
S
 
h
u
n
g
e
r
,
 
 
a
n
x
i
e
t
y
,
 
a
n
g
e
r
,
 
 
e
x
c
i
t
e
m
e
n
t
,
 
s
a
d
n
e
s
s
,
 
 
t
e
n
s
i
o
n
,
 
a
p
p
e
t
i
t
e
,
 
 
r
e
s
t
l
e
s
s
n
e
s
s
H
u
n
g
e
r
 
 
C
L
O
 
.
 
P
L
A
B
i
e
d
e
r
m
a
n
 
e
t
 
a
l
7
4
3
–
1
6
.
9
D
S
M
-
i
i
i
 
A
N
M
e
d
i
c
a
l
 
d
i
s
o
r
d
e
r
 
 
o
r
 
p
s
y
c
h
o
t
r
o
p
i
c
 
 
m
e
d
i
c
a
t
i
o
n
s
5
-
w
e
e
k
 
m
a
x
 
d
o
s
e
 
 
1
7
5
 
m
g
/
d
a
y
 
 
A
M
T
 
(
1
1
)
 
 
v
s
 
P
L
A
 
(
1
4
)
 
v
s
 
 
N
D
 
(
1
8
)
A
M
T
 
1
1
 
(
1
0
0
%
)
 
 
P
L
A
 
1
4
 
(
1
0
0
%
)
 
 
N
D
 
1
8
 
(
1
0
0
%
)
S
A
D
S
-
C
 
 
H
S
C
L
 
 
e
A
T
 
 
G
S
S
 
 
G
i
A
M
T
 
=
 
P
L
A
H
a
l
m
i
 
e
t
 
a
l
6
7
2
1
0
0
2
0
.
6
D
S
M
-
i
i
i
 
A
N
 
 
a
n
d
 
a
m
e
n
o
r
r
h
e
a
–
M
a
x
 
d
o
s
e
 
1
6
0
 
m
g
/
d
a
y
 
 
A
M
T
 
(
2
4
)
 
v
s
 
m
a
x
 
d
o
s
e
 
 
3
2
 
m
g
/
d
a
y
 
C
Y
P
 
(
2
3
)
 
v
s
 
 
P
L
A
 
(
2
5
)
A
M
T
 
1
8
 
(
7
5
%
)
 
 
C
Y
P
 
1
9
 
(
8
3
%
)
 
 
P
L
A
 
1
6
 
(
6
4
%
)
A
B
S
 
 
H
A
M
D
 
 
S
C
L
-
9
0
 
 
A
A
S
 
 
B
D
i
H
A
M
D
,
 
B
D
i
 
 
C
Y
P
 
.
 
P
L
A
R
u
g
g
i
e
r
o
 
e
t
 
a
l
5
3
5
–
2
4
.
1
D
S
M
-
i
v
 
A
N
-
R
 
 
s
u
b
t
y
p
e
,
 
c
o
m
p
l
e
t
i
n
g
 
 
i
n
p
a
t
i
e
n
t
 
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
A
g
e
 
,
 
1
7
 
y
e
a
r
s
,
 
 
p
s
y
c
h
i
a
t
r
i
c
 
 
c
o
m
o
r
b
i
d
i
t
y
3
 
m
o
n
t
h
s
 
m
a
x
 
d
o
s
e
 
 
5
8
 
m
g
 
C
L
O
 
(
1
3
)
 
v
s
 
m
a
x
 
 
d
o
s
e
 
2
8
 
m
g
 
F
L
X
 
(
1
0
)
 
v
s
 
m
a
x
 
 
d
o
s
e
 
5
0
 
m
g
 
A
M
S
 
(
1
2
)
C
L
O
 
1
3
 
(
1
0
0
%
)
 
 
F
L
X
 
1
0
 
(
1
0
0
%
)
 
 
A
M
S
 
1
2
 
(
1
0
0
%
)
B
M
i
 
 
L
i
F
e
 
i
i
 
B
e
i
w
e
i
g
h
t
 
A
M
S
 
.
 
 
C
L
O
 
a
n
d
 
F
L
X
S
e
l
e
c
t
i
v
e
 
s
e
r
o
t
o
n
i
n
 
r
e
u
p
t
a
k
e
 
i
n
h
i
b
i
t
o
r
s
A
t
t
i
a
 
e
t
 
a
l
8
3
3
1
0
0
2
6
.
2
F
,
 
a
g
e
 
1
6
–
4
5
 
y
e
a
r
s
,
 
 
D
S
M
-
i
v
 
A
N
,
 
 
m
e
d
i
c
a
l
l
y
 
s
t
a
b
l
e
F
L
X
 
a
l
l
e
r
g
y
,
 
a
l
c
o
h
o
l
 
 
o
r
 
d
r
u
g
 
d
e
p
e
n
d
e
n
c
e
 
i
n
 
 
p
a
s
t
 
6
 
m
o
n
t
h
s
,
 
b
i
p
o
l
a
r
 
 
o
r
 
p
s
y
c
h
o
t
i
c
 
i
l
l
n
e
s
s
,
 
O
C
D
 
 
w
i
t
h
 
o
n
s
e
t
 
p
r
i
o
r
 
t
o
 
A
N
∼
7
-
w
e
e
k
 
m
a
x
 
d
o
s
e
 
 
6
0
 
m
g
/
d
a
y
 
F
L
X
 
(
1
5
)
 
v
s
 
 
P
L
A
 
(
1
6
)
F
L
X
 
1
1
 
(
7
3
%
)
 
 
P
L
A
 
1
2
 
(
7
5
%
)
A
B
S
 
 
B
D
i
 
 
C
G
i
 
 
B
S
Q
 
 
e
A
T
 
 
S
C
L
-
9
0
 
 
Y
B
C
-
e
D
F
L
X
 
=
 
P
L
A
K
a
y
e
 
e
t
 
a
l
1
0
3
9
1
0
0
2
2
.
5
F
,
 
D
S
M
-
i
v
 
A
N
 
 
(
w
h
i
l
e
 
u
n
d
e
r
w
e
i
g
h
t
)
B
i
n
g
e
 
e
a
t
i
n
g
,
 
S
e
v
e
r
e
 
 
m
e
d
i
c
a
l
 
o
r
 
n
e
u
r
o
l
o
g
i
c
 
i
l
l
n
e
s
s
,
 
 
s
c
h
i
z
o
p
h
r
e
n
i
a
,
 
a
l
c
o
h
o
l
 
 
o
r
 
d
r
u
g
 
d
e
p
e
n
d
e
n
c
e
 
i
n
 
 
p
a
s
t
 
y
e
a
r
,
 
p
s
y
c
h
o
t
r
o
p
i
c
 
 
m
e
d
i
c
a
t
i
o
n
 
i
n
 
p
a
s
t
 
m
o
n
t
h
O
n
e
-
y
e
a
r
 
p
o
s
t
 
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
 
m
a
x
 
 
d
o
s
e
 
6
0
 
m
g
/
d
a
y
 
 
F
L
X
 
(
1
9
)
 
v
s
 
P
L
A
 
(
2
0
)
F
L
X
 
1
0
 
(
6
3
%
)
 
 
P
L
A
 
3
 
(
1
5
%
)
T
r
e
a
t
m
e
n
t
 
 
c
o
m
p
l
e
t
i
o
n
 
 
H
D
R
S
 
 
H
A
R
S
 
 
Y
B
O
C
S
 
 
Y
B
C
-
e
D
w
T
,
 
H
D
R
S
,
 
 
H
A
R
S
,
 
Y
B
O
C
S
,
 
 
Y
B
C
-
e
D
 
i
m
p
r
o
v
e
d
 
w
i
t
h
 
F
L
X
F
a
s
s
i
n
o
 
e
t
 
a
l
1
1
5
2
1
0
0
2
4
.
8
A
N
-
R
,
 
 
a
g
e
 
1
6
–
3
5
 
y
e
a
r
s
P
s
y
c
h
o
t
r
o
p
i
c
 
m
e
d
i
c
a
t
i
o
n
 
i
n
 
 
p
a
s
t
 
m
o
n
t
h
,
 
p
s
y
c
h
i
a
t
r
i
c
 
c
o
m
o
r
b
i
d
i
t
y
,
 
 
k
n
o
w
n
 
s
e
n
s
i
t
i
v
i
t
y
 
t
o
 
C
i
T
1
2
 
w
e
e
k
s
 
m
a
x
 
d
o
s
e
 
 
2
0
 
m
g
/
d
a
y
 
 
C
i
T
 
(
2
6
)
 
v
s
 
 
w
L
 
(
2
6
)
C
i
T
 
1
9
 
(
7
3
%
)
 
 
w
L
 
2
0
 
(
7
7
%
)
B
M
i
 
e
D
i
 
e
D
i
-
S
C
 
 
S
T
A
X
i
 
B
D
i
 
S
C
L
-
9
0
B
D
i
,
 
S
T
A
X
i
,
 
e
D
i
 
C
i
T
 
.
 
w
L
(
C
o
n
t
i
n
u
e
d
)Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
94
Bodell and Keel
T
a
b
l
e
 
1
 
(
C
o
n
t
i
n
u
e
d
)
R
e
f
e
r
e
n
c
e
n
S
e
x
 
 
(
%
 
F
)
A
g
e
,
 
y
e
a
r
s
 
 
(
m
e
d
i
a
n
)
I
n
c
l
u
s
i
o
n
 
 
c
r
i
t
e
r
i
a
E
x
c
l
u
s
i
o
n
 
 
c
r
i
t
e
r
i
a
T
r
e
a
t
m
e
n
t
 
 
c
o
n
d
i
t
i
o
n
s
T
r
e
a
t
m
e
n
t
 
 
c
o
m
p
l
e
t
i
o
n
O
u
t
c
o
m
e
 
 
m
e
a
s
u
r
e
s
R
e
s
u
l
t
s
 
 
s
u
m
m
a
r
y
*
*
B
a
r
b
a
r
i
c
h
 
e
t
 
a
l
6
4
2
6
–
2
3
A
N
–
S
i
x
 
m
o
n
t
h
s
 
m
a
x
 
 
d
o
s
e
 
6
0
 
m
g
/
d
a
y
 
 
F
L
X
 
+
 
N
S
 
(
1
5
)
 
v
s
 
 
F
L
X
 
+
 
P
L
A
 
(
1
1
)
F
L
X
 
+
 
N
S
 
7
 
(
4
7
%
)
 
 
F
L
X
 
+
 
P
L
A
 
2
 
(
1
8
%
)
w
T
 
g
a
i
n
 
 
F
M
P
S
 
 
S
T
A
i
 
 
Y
B
O
C
S
F
L
X
 
+
 
N
S
 
=
 
 
F
L
X
 
+
 
P
L
A
w
a
l
s
h
 
e
t
 
a
l
9
9
3
1
0
0
2
3
.
3
F
,
 
a
g
e
 
1
6
–
4
5
 
y
e
a
r
s
,
 
 
D
S
M
-
i
v
 
A
N
 
 
(
e
x
c
e
p
t
 
 
a
m
e
n
o
r
r
h
e
a
)
,
 
 
c
u
r
r
e
n
t
 
B
M
i
 
$
 
 
1
9
 
k
g
/
m
2
 
f
o
r
 
 
a
t
 
l
e
a
s
t
 
2
 
w
e
e
k
s
i
m
m
i
n
e
n
t
 
s
u
i
c
i
d
e
 
r
i
s
k
,
 
 
s
e
r
i
o
u
s
 
m
e
d
i
c
a
l
 
i
l
l
n
e
s
s
,
 
 
c
u
r
r
e
n
t
 
p
s
y
c
h
o
t
r
o
p
i
c
 
 
m
e
d
i
c
a
t
i
o
n
O
n
e
 
y
e
a
r
 
m
a
x
 
 
d
o
s
e
 
8
0
 
m
g
/
d
a
y
 
 
F
L
X
 
+
 
C
B
T
 
(
4
9
)
 
v
s
 
 
P
L
A
 
+
 
C
B
T
 
(
4
4
)
F
L
X
 
2
4
 
(
4
9
%
)
 
 
P
L
A
 
1
6
 
(
3
6
%
)
T
i
m
e
-
t
o
-
r
e
l
a
p
s
e
 
 
B
M
i
 
 
e
D
i
 
 
B
D
i
 
 
B
A
i
 
 
R
S
e
 
 
Y
B
C
-
e
D
 
 
Q
l
e
s
Q
B
A
i
 
 
F
L
X
 
.
 
P
L
A
A
n
t
i
p
s
y
c
h
o
t
i
c
s
v
a
n
d
e
r
e
y
c
k
e
n
 
 
a
n
d
 
P
i
e
r
l
o
o
t
1
2
1
8
1
0
0
(
2
1
.
5
)
D
S
M
-
i
i
i
 
A
N
A
d
d
i
t
i
o
n
a
l
 
d
r
u
g
 
 
t
r
e
a
t
m
e
n
t
6
 
w
e
e
k
s
 
d
o
s
e
 
4
 
o
r
 
 
6
 
m
g
/
d
a
y
 
P
i
M
 
(
8
)
 
v
s
 
 
P
L
A
 
(
1
0
)
 
 
c
r
o
s
s
o
v
e
r
 
d
e
s
i
g
n
P
i
M
 
7
 
(
8
8
%
)
 
 
P
L
A
 
1
0
 
(
1
0
0
%
)
A
B
S
 
 
w
T
 
g
a
i
n
w
T
 
g
a
i
n
 
 
P
i
M
 
.
 
P
L
A
v
a
n
d
e
r
e
y
c
k
e
n
1
3
1
8
1
0
0
2
3
.
5
D
S
M
-
i
i
i
 
A
N
A
d
d
i
t
i
o
n
a
l
 
d
r
u
g
 
 
t
r
e
a
t
m
e
n
t
6
 
w
e
e
k
s
 
 
m
e
a
n
 
d
o
s
e
 
 
3
2
5
 
m
g
 
S
U
L
 
(
9
)
 
v
s
 
 
P
L
A
 
(
9
)
 
c
r
o
s
s
o
v
e
r
 
d
e
s
i
g
n
S
U
L
 
9
 
(
1
0
0
%
)
 
 
P
L
A
 
9
 
(
1
0
0
%
)
A
B
S
 
 
e
A
T
 
 
B
A
T
 
 
w
T
 
g
a
i
n
S
U
L
 
=
 
P
L
A
M
o
n
d
r
a
t
y
 
e
t
 
a
l
1
4
1
5
–
2
5
.
3
D
S
M
-
i
v
 
A
N
–
∼
7
 
w
e
e
k
s
 
m
a
x
 
d
o
s
e
 
 
2
0
 
m
g
/
d
a
y
 
O
L
Z
 
(
8
)
 
v
s
 
 
m
a
x
 
d
o
s
e
 
2
0
0
 
m
g
/
d
a
y
 
 
C
H
L
 
(
7
)
O
L
Z
 
8
 
(
1
0
0
%
)
 
 
C
H
L
 
7
 
(
1
0
0
%
)
w
T
 
g
a
i
n
 
 
e
D
i
-
2
 
P
i
P
i
 
r
u
m
i
n
a
t
i
v
e
 
t
h
i
n
k
i
n
g
 
 
O
L
Z
 
.
 
C
H
L
B
r
a
m
b
i
l
l
a
 
e
t
 
a
l
1
5
3
0
1
0
0
2
5
D
S
M
-
i
v
 
A
N
G
e
n
e
r
a
l
 
m
e
d
i
c
a
l
 
 
i
m
p
a
i
r
m
e
n
t
s
,
 
c
e
r
e
b
r
a
l
 
 
t
r
a
u
m
a
,
 
e
p
i
l
e
p
s
y
3
 
m
o
n
t
h
s
 
m
a
x
 
d
o
s
e
 
 
5
 
m
g
/
d
a
y
 
 
O
L
Z
 
+
 
C
B
T
 
(
1
5
)
 
v
s
 
 
 
P
L
A
 
+
 
C
B
T
 
(
1
5
)
O
L
Z
 
1
5
 
(
1
0
0
%
)
 
 
P
L
A
 
1
5
 
(
1
0
0
%
)
B
M
i
 
 
e
D
i
 
 
Y
B
C
-
e
D
 
 
B
D
S
A
 
 
H
A
M
D
 
 
T
C
i
Y
B
C
-
e
D
 
c
o
m
p
u
l
s
i
v
i
t
y
 
 
O
L
Z
 
.
 
P
L
A
 
 
B
D
S
A
 
d
i
r
e
c
t
 
a
g
g
r
e
s
s
i
o
n
 
 
O
L
Z
 
.
 
P
L
A
 
 
H
A
M
D
 
O
L
Z
 
.
 
P
L
A
 
 
T
C
i
 
p
e
r
s
i
s
t
e
n
c
e
 
O
L
Z
 
.
 
P
L
A
B
i
s
s
a
d
a
 
e
t
 
a
l
1
6
3
4
1
0
0
2
6
.
8
D
S
M
-
i
v
 
A
N
 
 
(
e
x
c
e
p
t
 
 
a
m
e
n
o
r
r
h
e
a
)
A
c
t
i
v
e
 
s
u
i
c
i
d
a
l
 
i
n
t
e
n
t
,
 
 
c
o
m
o
r
b
i
d
 
s
u
b
s
t
a
n
c
e
 
u
s
e
,
 
 
b
i
p
o
l
a
r
,
 
s
c
h
i
z
o
p
h
r
e
n
i
a
 
o
r
 
 
o
t
h
e
r
 
p
s
y
c
h
o
t
i
c
 
d
i
s
o
r
d
e
r
,
 
 
p
r
e
g
n
a
n
c
y
,
 
p
s
y
c
h
o
t
r
o
p
i
c
 
 
m
e
d
i
c
a
t
i
o
n
s
 
2
 
w
e
e
k
s
 
p
r
i
o
r
 
 
t
o
 
s
t
u
d
y
 
i
n
i
t
i
a
t
i
o
n
1
0
 
w
e
e
k
 
m
a
x
 
d
o
s
e
 
 
6
.
6
1
 
m
g
/
d
a
y
 
 
O
L
Z
 
+
 
D
H
 
(
1
6
)
 
v
s
 
 
P
L
A
 
+
 
D
H
 
(
1
8
)
O
L
Z
 
1
4
 
(
8
8
%
)
 
 
P
L
A
 
1
4
 
(
7
8
%
)
B
M
i
 
 
P
A
S
 
 
Y
B
O
C
S
w
T
 
g
a
i
n
 
 
O
L
Z
 
.
 
P
L
A
 
 
Y
B
O
C
S
 
o
b
s
e
s
s
i
o
n
s
 
 
O
L
Z
 
.
 
P
L
APsychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
95
Current treatment for anorexia nervosa
O
t
h
e
r
 
a
g
e
n
t
s
G
r
o
s
s
 
e
t
 
a
l
1
7
1
6
1
0
0
1
9
.
8
A
N
 
(
F
e
i
g
h
n
e
r
 
e
t
 
a
l
 
 
c
r
i
t
e
r
i
a
)
6
5
–
4
 
w
e
e
k
s
 
 
L
C
 
(
8
)
 
v
s
 
 
P
L
A
 
(
8
)
L
C
 
8
 
(
1
0
0
%
)
 
 
P
L
A
 
8
 
(
1
0
0
%
)
w
T
 
g
a
i
n
 
 
H
S
C
L
-
9
0
 
 
G
A
A
Q
 
 
S
D
S
 
 
P
R
S
w
T
 
g
a
i
n
 
 
L
C
 
.
 
P
L
A
S
z
m
u
k
l
e
r
 
e
t
 
a
l
1
8
2
9
–
2
1
.
9
D
S
M
-
i
i
i
-
R
 
A
N
,
 
 
a
g
e
 
1
8
–
4
0
 
y
e
a
r
s
C
o
n
c
u
r
r
e
n
t
 
i
l
l
n
e
s
s
 
 
a
f
f
e
c
t
i
n
g
 
g
a
s
t
r
i
c
 
e
m
p
t
y
i
n
g
8
 
w
e
e
k
 
m
a
x
 
 
d
o
s
e
 
3
0
 
m
g
 
 
C
i
S
 
(
1
6
)
 
v
s
 
 
P
L
A
 
(
1
3
)
C
i
S
 
1
6
 
(
1
0
0
%
)
 
 
P
L
A
 
1
3
 
(
1
0
0
%
)
w
T
 
 
H
e
T
 
 
v
A
S
 
 
B
D
i
 
 
G
i
v
A
S
 
h
u
n
g
e
r
 
 
C
i
S
 
.
 
P
L
A
 
 
G
i
 
 
C
i
S
 
.
 
P
L
A
N
o
t
e
:
 
*
*
G
r
e
a
t
e
r
 
t
h
a
n
 
s
y
m
b
o
l
 
(
.
)
 
r
e
f
e
r
s
 
t
o
 
a
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
b
e
t
t
e
r
 
o
u
t
c
o
m
e
 
o
r
 
i
m
p
r
o
v
e
m
e
n
t
.
 
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
A
S
,
 
A
n
o
r
e
c
t
i
c
 
A
t
t
i
t
u
d
e
s
 
S
c
a
l
e
;
 
A
B
S
,
 
a
n
o
r
e
x
i
c
 
b
e
h
a
v
i
o
r
 
s
c
a
l
e
;
 
A
M
S
,
 
a
m
i
s
u
l
p
r
i
d
e
;
 
A
M
T
,
 
a
m
i
t
r
i
p
t
y
l
i
n
e
;
 
B
A
i
,
 
B
e
c
k
 
A
n
x
i
e
t
y
 
i
n
v
e
n
t
o
r
y
;
 
B
A
T
,
 
B
o
d
y
 
A
t
t
i
t
u
d
e
s
 
T
e
s
t
;
 
B
D
i
,
 
B
e
c
k
 
D
e
p
r
e
s
s
i
o
n
 
i
n
v
e
n
t
o
r
y
;
 
B
D
S
A
,
 
B
u
s
s
–
D
u
r
k
e
e
 
S
c
a
l
e
 
F
o
r
 
A
g
g
r
e
s
s
i
o
n
;
 
B
M
i
,
 
b
o
d
y
 
m
a
s
s
 
i
n
d
e
x
;
 
B
S
Q
,
 
B
o
d
y
 
S
h
a
p
e
 
Q
u
e
s
t
i
o
n
n
a
i
r
e
;
 
C
B
T
,
 
c
o
g
n
i
t
i
v
e
 
b
e
h
a
v
i
o
r
a
l
 
t
h
e
r
a
p
y
;
 
C
G
i
,
 
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
i
m
p
r
e
s
s
i
o
n
;
 
C
H
L
,
 
c
h
l
o
r
p
r
o
m
a
z
i
n
e
;
 
C
i
S
,
 
c
i
s
a
p
r
i
d
e
;
 
C
i
T
,
 
c
i
t
a
l
o
p
r
a
m
;
 
C
L
O
,
 
c
l
o
m
i
p
r
a
m
i
d
e
;
 
C
Y
P
,
 
c
y
p
r
o
h
e
p
t
a
d
i
n
e
;
 
D
H
,
 
d
a
y
 
h
o
s
p
i
t
a
l
;
 
E
A
T
,
 
E
a
t
i
n
g
 
A
t
t
i
t
u
d
e
s
 
T
e
s
t
;
 
E
D
I
,
 
E
a
t
i
n
g
 
D
i
s
o
r
d
e
r
 
I
n
v
e
n
t
o
r
y
;
 
E
D
I
-
S
C
,
 
E
a
t
i
n
g
 
D
i
s
o
r
d
e
r
 
I
n
v
e
n
t
o
r
y
 
S
y
m
p
t
o
m
 
C
h
e
c
k
l
i
s
t
;
 
F
,
 
f
e
m
a
l
e
;
 
F
L
X
,
 
fl
u
o
x
e
t
i
n
e
;
 
F
M
P
S
,
 
F
r
o
s
t
 
M
u
l
t
i
d
i
m
e
n
s
i
o
n
a
l
 
P
e
r
f
e
c
t
i
o
n
i
s
m
 
S
c
a
l
e
;
 
G
A
A
Q
,
 
G
o
l
d
b
e
r
g
 
A
n
o
r
e
c
t
i
c
 
A
t
t
i
t
u
d
e
 
Q
u
e
s
t
i
o
n
n
a
i
r
e
;
 
G
i
,
 
g
l
o
b
a
l
 
i
m
p
r
o
v
e
m
e
n
t
;
 
G
S
S
,
 
G
l
o
b
a
l
 
S
e
v
e
r
i
t
y
 
S
c
a
l
e
;
 
H
A
R
S
,
 
H
a
m
i
l
t
o
n
 
A
n
x
i
e
t
y
 
R
a
t
i
n
g
 
S
c
a
l
e
;
 
H
D
R
S
,
 
H
a
m
i
l
t
o
n
 
D
e
p
r
e
s
s
i
o
n
 
R
a
t
i
n
g
 
S
c
a
l
e
;
 
H
e
T
,
 
g
a
s
t
r
i
c
 
h
a
l
f
-
e
m
p
t
y
i
n
g
 
t
i
m
e
;
 
H
S
C
L
,
 
H
o
p
k
i
n
s
 
S
y
m
p
t
o
m
 
C
h
e
c
k
l
i
s
t
;
 
L
C
,
 
l
i
t
h
i
u
m
 
c
a
r
b
o
n
a
t
e
;
 
L
i
F
e
 
i
i
 
B
e
i
,
 
s
t
r
u
c
t
u
r
e
d
 
e
a
t
i
n
g
 
d
i
s
o
r
d
e
r
 
i
n
t
e
r
v
i
e
w
 
b
a
s
e
d
 
o
n
 
l
o
n
g
 
i
n
t
e
r
v
a
l
 
f
o
l
l
o
w
-
u
p
 
e
v
a
l
u
a
t
i
o
n
;
 
N
D
,
 
n
o
 
d
r
u
g
 
g
r
o
u
p
;
 
N
S
,
 
n
u
t
r
i
t
i
o
n
a
l
 
s
u
p
p
l
e
m
e
n
t
;
 
O
L
Z
,
 
o
l
a
n
z
a
p
i
n
e
;
 
P
A
S
,
 
P
e
r
s
o
n
a
l
i
t
y
 
A
s
s
e
s
s
m
e
n
t
 
i
n
v
e
n
t
o
r
y
;
 
P
i
,
 
P
a
d
u
a
 
i
n
v
e
n
t
o
r
y
;
 
P
i
M
,
 
p
i
m
o
z
i
d
e
;
 
P
L
A
,
 
p
l
a
c
e
b
o
;
 
P
R
S
,
 
P
s
y
c
h
i
a
t
r
i
c
 
R
a
t
i
n
g
 
S
c
a
l
e
;
 
Q
l
e
s
Q
,
 
q
u
a
l
i
t
y
 
o
f
 
l
i
f
e
 
e
n
j
o
y
m
e
n
t
 
a
n
d
 
s
a
t
i
s
f
a
c
t
i
o
n
 
q
u
e
s
t
i
o
n
n
a
i
r
e
;
 
R
S
e
,
 
R
o
s
e
n
b
e
r
g
 
S
e
l
f
-
e
s
t
e
e
m
 
S
c
a
l
e
;
 
S
A
D
S
-
C
,
 
A
f
f
e
c
t
i
v
e
 
D
i
s
o
r
d
e
r
s
 
a
n
d
 
S
c
h
i
z
o
p
h
r
e
n
i
a
-
c
h
a
n
g
e
 
v
e
r
s
i
o
n
;
 
S
C
L
,
 
s
y
m
p
t
o
m
s
 
c
h
e
c
k
l
i
s
t
;
 
S
D
S
,
 
G
o
l
d
b
e
r
g
 
S
i
t
u
a
t
i
o
n
a
l
 
D
i
s
c
o
m
f
o
r
t
 
S
c
a
l
e
;
 
S
T
A
i
,
 
S
t
a
t
e
 
T
r
a
i
t
 
A
n
x
i
e
t
y
 
i
n
v
e
n
t
o
r
y
;
 
S
T
A
X
i
,
 
S
t
a
t
e
 
T
r
a
i
t
 
A
n
g
e
r
 
e
x
p
r
e
s
s
i
o
n
 
i
n
v
e
n
t
o
r
y
;
 
S
U
L
,
 
s
u
l
p
i
r
i
d
e
;
 
T
C
i
,
 
T
e
m
p
e
r
a
m
e
n
t
 
a
n
d
 
C
h
a
r
a
c
t
e
r
 
i
n
v
e
n
t
o
r
y
;
 
v
A
S
,
 
v
i
s
u
a
l
 
a
n
a
l
o
g
 
s
c
a
l
e
;
 
w
L
,
 
w
a
i
t
-
l
i
s
t
;
 
w
T
,
 
w
e
i
g
h
t
;
 
Y
B
C
-
e
D
,
 
Y
a
l
e
–
B
r
o
w
n
–
C
o
r
n
e
l
l
 
e
a
t
i
n
g
 
D
i
s
o
r
d
e
r
 
S
c
a
l
e
;
 
Y
B
O
C
S
,
 
Y
a
l
e
–
B
r
o
w
n
 
O
b
s
e
s
s
i
v
e
–
C
o
m
p
u
l
s
i
v
e
 
S
c
a
l
e
.
picture of lack of efficacy for fluoxetine in promoting the 
maintenance phase of treatment for AN.
Lastly, one RCT revealed some potential benefits of 
  citalopram, an SSRI, in the treatment of outpatients with 
AN. Fassino et al11 found that compared with wait-list 
controls (who were monitored with periodic clinical assess-
ments to ensure safety), citalopram was associated with 
improvements in depression, anxiety, and some ED symp-
toms; however, citalopram was not effective in increasing 
weight. Additionally, this study is limited by its use of a 
wait-list rather than a placebo control group. Thus, further 
evidence is needed to determine the efficacy of citalopram 
in the treatment of AN.
Adherence
In general, there were no differences in adherence for 
the TCAs compared with other medication groups (eg, 
placebo, amisulpride, fluoxetine, and cyproheptadine). 
In one study, treatment compliance for amitriptyline was 
good, with only two patients showing lower than expected 
plasma levels of the medication.7 In terms of the SSRIs, 
adherence to fluoxetine in hospitalized patients with AN 
was also good.8 There were no reported differences in 
treatment compliance between fluoxetine and placebo, 
with two patients in each group leaving treatment prema-
turely against medical advice.8 Treatment completion rates 
in the two studies examining the effect of fluoxetine in 
weight-restored patients with AN at one year were 63%10 
and 49%,9 respectively. Citalopram had a relatively high 
rate of treatment compliance (73%), which did not differ 
from placebo.11
Safety
In the early study of clomipramine versus placebo as 
adjunctive treatment to inpatient hospitalization, two of 
16 patients, both of whom purged, complained of side 
effects normally attributed to TCA medications, but one 
patient was on placebo.4 In one study, the majority of 
patients treated with amitriptyline experienced substantial 
discomfort and adverse effects including diaphoresis, 
drowsiness, dry mouth, blurred vision, urinary reten-
tion, hypotension, and cardiovascular problems.7 Unlike 
amitriptyline, fluoxetine appears to be well tolerated by 
patients both in the acute and weight maintenance phases 
of treatment. The most common side effects or reasons for 
discontinuing treatment with fluoxetine during the inpatient 
treatment trial were persistent or worsening depression or 
anxiety, headaches, insomnia, and agitation.8Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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Summary
Overall, the TCA class of antidepressants appears to be 
ineffective in the treatment of AN, with some specific medi-
cations (ie, amitriptyline) associated with significant side 
effects. On the other hand, the SSRI class of antidepressants 
appears well tolerated by AN patients, with only mild side 
effects. However, SSRIs do not appear to be effective in 
treating symptoms of AN or preventing relapse.
Antipsychotics
Various antipsychotics have been evaluated in the treatment of 
AN, because affected individuals show distorted body image 
to a delusional proportion and because of the ego-syntonic 
nature of self-starvation. Furthermore, antipsychotics are 
known to reduce agitation and anxiety and often have weight 
gain as a side effect.
Efficacy
Early trials of antipsychotics have evaluated the effects of 
pimozide, a dopamine receptor blocker,12 and sulpiride, 
a selective dopamine antagonist.13 Vandereycken and 
  Pierloot12 used a double-blind, crossover design with 
three-week medication periods of pimozide and placebo. 
Results provide modest support for enhanced weight gain 
using pimozide compared with placebo, but findings were 
limited by a small sample size (n = 18) and a short dura-
tion of   treatment (ie, three weeks of medication). Using 
nearly identical   methods to those in the pimozide trial, 
Vandereycken13 found no benefits of sulpiride compared 
with placebo.
The most widely studied antipsychotic medication 
for AN is olanzapine, a thienobenzodiazepine with high 
affinity for serotonin and dopamine receptors. Olanzapine 
has been compared with both placebo and chlorpromaz-
ine (a typical antipsychotic) in RCTs. There is growing 
evidence to suggest that olanzapine may be beneficial in 
the treatment of AN, but the nature of such improvements 
has varied across studies. In a seven-week trial, olanzap-
ine was more effective than chlorpromazine in reducing 
ruminative anorexic thinking in inpatients with AN.14 In 
a three-month outpatient trial of olanzapine versus pla-
cebo in women receiving CBT, olanzapine was associated 
with improvements in depression, aggressiveness, and 
ED-related compulsivity.15 When patients were stratified 
by AN subtype, there was a significant increase in body 
mass index for those with AN binge-purge subtype in the 
olanzapine group, suggesting that olanzapine may be more 
beneficial in increasing weight for a subgroup of those 
with AN. In a 10-week trial of olanzapine versus placebo 
in a larger sample of women in a day-hospital program, 
Bissada et al16 found that olanzapine was significantly 
better than placebo in increasing rate of weight gain and 
decreasing obsessions.
Adherence
Treatment adherence to pimozide and sulpiride was good, 
with one patient discontinuing treatment with pimozide 
due to side effects.12 Treatment compliance was also high 
in patients taking chlorpromazine (100%) and olanzapine 
(88%–100%).
Safety
One patient in the pimozide trial reported severe central 
nervous system side effects and had to be withdrawn 
from the study.12 Furthermore, the evidence suggests 
that higher doses of pimozide are usually associated with 
central nervous system adverse effects, and these may 
be more pronounced in underweight individuals.12 In a 
small trial of chlorpromazine versus olanzapine, chlo-
rpromazine was associated with side effects including 
sedation, hypotension, and blurred vision in the major-
ity (50%) of patients.14 In contrast, olanzapine has been 
well tolerated by individuals with AN and has not been 
associated with reports of serious adverse effects.14–16 
The most frequently reported side effect for olanzapine 
was mild sleepiness.15
Summary
Although antipsychotics appear to be reasonably well 
tolerated by individuals with AN, some are associated with 
severe side effects, and those associated with the worst side 
effects do not appear to be associated with large improve-
ments in treating the disorder. Of note, preliminary evidence 
suggests that olanzapine is well tolerated, associated with 
only mild side effects, and may be effective in improving 
some cognitive symptoms and weight.
Other agents
Other pharmacologic agents have been tried in the treatment 
of AN, including lithium carbonate (a mood stabilizer), 
cyproheptadine hydrochloride, and cisapride. Similar to 
some of the antipsychotic medications, lithium carbon-
ate and cyproheptadine were evaluated in the treatment of 
AN because of their associations with weight gain in other 
populations. On the other hand, cisapride was evaluated in 
AN due to its known effect on increasing the rate of gastric Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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emptying, which was hypothesized to decrease distress from 
feelings of fullness and bloating during refeeding.
Efficacy
There is some indication that lithium may facilitate weight 
gain in individuals with AN, but results are limited by 
small sample size and need for replication.17 As previously 
noted, one RCT found cyproheptadine to be associated with 
decreased rates of depression and increased improvements 
in those without bulimic symptoms, but it was associated 
with decreased efficacy in individuals with bulimic symp-
toms.6 Lastly, in an eight-week trial of cisapride versus pla-
cebo, cisapride led to improvements in hunger and reductions 
in overall distress, but it did not prove helpful in increasing 
weight or ameliorating psychological symptoms.18
Adherence
Treatment compliance for lithium (100%), cyproheptadine 
(83%), and cisapride (100%) were good. 
Safety
Although there was a slight indication that lithium facilitated 
weight gain in a small sample, concerns have been raised that 
the use of lithium in individuals who may not be medically 
stable, and often exhibit electrolyte and fluid imbalances, 
may present safety issues that compromise any beneficial 
effects.19 Cyproheptadine was not associated with any pattern 
of moderately or severely rated physical symptoms or side 
effects in AN patients.6
Psychological treatments
A variety of psychological treatments for AN have attempted 
to target different aspects of the disorder, including distorted 
thoughts regarding food and body image, dysfunctional 
behaviors such as restrictive eating, binging and purging, 
and interpersonal and intrapsychic issues. To date, CBT has 
been the most frequently studied psychological treatment for 
AN in adults, and family therapy has gained evidence for the 
treatment of AN in adolescents.
Cognitive behavioral therapy
CBT for AN is based on a theoretical model that overvalued 
ideas about the significance of shape, weight, and control 
over eating are the maintaining factors of the disorder. 
In general, the treatment can be divided into four phases, 
ie, enhancement of motivation, targeting of cognitive 
distortions and dysfunctional behavior related to eating 
habits and shape or weight, issues beyond eating and weight, 
and relapse prevention.20 Five RCTs have been conducted 
comparing similar versions of CBT and cognitive therapy 
with other forms of psychotherapy or dietary or nutritional 
counseling. Four of these trials have been conducted with 
individuals in the acute phase of treatment,21–24 and one with 
weight-restored AN patients.25
Efficacy
Results from studies comparing CBT with other forms of 
behavioral therapy (BT) indicate that there is no difference 
between the two types of treatments in individuals with AN, 
but these trials are limited by small sample sizes.21,23 The 
first controlled trial of CBT for AN compared six months 
of outpatient CBT with BT and “treatment as usual” in 
24 females. CBT and BT did not differ from each other in 
terms of improvements in weight, eating disorder symptoms, 
or Morgan–Russell status.21 Similarly, Ball and Mitchell23 
conducted a study comparing CBT with behavioral family 
therapy in women aged 13–23 years. Although this study had 
a greater length of treatment (one year) and longer duration of 
follow-up (six months) than the previous study, it also found 
no differences between the two treatments.
Given that individuals with AN often experience a range of 
interpersonal problems26 and evidence that interpersonal therapy 
had efficacy in the treatment of BN compared with BT,27 McIn-
tosh et al24 compared the effectiveness of 20 weeks of outpatient 
CBT with interpersonal psychotherapy and nonspecific support-
ive clinical management in a group of 56 adult women with AN. 
Individuals in the nonspecific supportive clinical management 
group showed greater global improvement than both the CBT 
and interpersonal therapy groups, but there were no differences 
between the groups in terms of weight outcome.
Lastly, CBT and cognitive therapy have both been 
  compared with dietary and nutritional counseling in 
  outpatients with AN. Serfaty et al22 found that weight, 
depression, and ED symptoms all improved with cogni-
tive therapy in a sample of 35 adult outpatients with AN. 
  However, all 10 individuals in the nutritional counseling 
control group dropped out, so no specific comparisons 
between the groups could be made at treatment end. Only 
one RCT has been conducted examining the efficacy of 
CBT in preventing relapse in individuals with AN compared 
with nutritional counseling.25 This study found that CBT 
was associated with significantly greater treatment suc-
cess and longer time to relapse compared with nutritional 
counseling. Results suggest that CBT may be helpful in 
preventing relapse in weight-restored women with AN at 
least one year following discharge from inpatient treatment, Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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but replication is important given problems with failure to 
replicate positive results from other RCTs.
Adherence
Treatment completion rates for CBT in RCTs have ranged 
from 63%–100%, suggesting CBT is reasonably well 
tolerated by patients with AN. Additionally, adherence 
to treatment with both CBT and behavioral therapies has 
been significantly better than control conditions, including 
nutritional counseling and dietary advice. Despite reason-
able rates of treatment completion in CBT trials, no studies 
report compliance with homework or other aspects of the 
treatment, so rates of full engagement with the treatment 
protocol are unknown.
Safety
Although CBT is itself a “safe” treatment, some patients 
require hospitalization during treatment to address medical 
safety. In one study, three patients (12%) had to be withdrawn 
from CBT or behavioral therapy and be hospitalized.23
Summary
Overall, there is some limited support for CBT improving 
symptoms of AN or reducing rate of relapse when compared 
with “nutritional” therapies, but conclusions are limited by 
lack of a sustained control group for one study and lack of 
replication for the other. Moreover, in larger trials, CBT 
does not seem superior to other forms of psychotherapy 
(eg,   behavioral therapy, nonspecific supportive clinical 
management).
Family therapy
As previously mentioned, there is growing evidence for the 
efficacy of family therapy in the treatment of adolescents 
with AN. To date, seven RCTs have been conducted in ado-
lescent populations, with the majority (five) being family 
therapy interventions. Family therapy appears superior when 
compared with other forms of psychotherapy, and results do 
not appear dependent on the format (eg, individual versus 
group) or length of treatment. Early theories of the devel-
opment of AN assumed that dysfunctional family life was 
one of the causes of the disorder. As such, family therapy 
interpreted patients with AN as the “identified patient” 
and sought to treat the family system because the entire 
family was viewed as the actual patient. In stark contrast, 
the current rationale for family therapy does not blame the 
family for the emergence of AN, and instead is based on the 
idea that the family environment can be used to ameliorate 
the disorder. Thus, modern family therapies invite family 
members to become part of the treatment team to extend a 
therapeutic environment for change into patients’ natural-
istic environments.
Efficacy
Russell et al28 conducted the first RCT to examine the 
efficacy of family therapy. All participants were admitted 
to the Maudsley Hospital in London and weight restored to 
at least 89.5% of average body weight. Patients were first 
stratified into one of four subgroups and then randomly 
assigned to either one year of outpatient family therapy 
or individual supportive therapy just prior to discharge. 
The subgroups consisted of early-onset AN with duration 
less than three years (mean age 16.6 years), early-onset 
AN with duration greater than three years (mean age 
20.6 years), AN age of onset greater than 19 years (mean 
age 27.7 years), and BN (mean age 24.0 years). Results 
indicated that family therapy was superior to individual 
supportive therapy for the early-onset/short duration AN 
subgroup, suggesting that family therapy may be benefi-
cial for a specific subgroup of AN patients. In contrast, 
individual supportive therapy led to greater improvements 
in body weight and better Morgan–Russell outcomes29 
compared with family therapy for adults with AN (ie, 
later-onset group). In another early outpatient trial of 
combined individual and family therapy versus dietary 
advice conducted in adults with AN, Hall and Crisp30 found 
that, at one-year follow-up, individuals in the combined 
treatment group showed significant improvements in sexual 
and social adjustment compared with the dietary advice 
treatment group; however, no differences were found for 
improvements in weight. In the second study of adolescent 
patients, body mass index was significantly more improved 
at one-year follow-up in adolescent girls treated with 
behavioral systems family therapy compared with those 
treated with ego-oriented individual therapy.31
Based on results indicating general benefits of   family 
therapy in adolescents, studies have examined various 
permutations of family therapy, including conjoint versus 
separate treatment sessions,32–34 individual versus group 
  family therapy,35 and short-term versus long-term 
  treatment.36 Two studies comparing conjoint (ie, sessions 
with both the patient and parents) versus separate family 
therapy (ie, individual sessions for the patient and separate 
counseling sessions for the parents) found no differences 
between groups after six months32 or at five-year follow-
up.34 Additionally, five-year follow-up revealed that Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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individuals with families high in expressed emotion 
(maternal criticism) in the conjoint family group were less 
likely to experience continued weight gain after treatment, 
whereas those low in expressed emotion continued weight 
gain regardless of treatment group.
In a comparison of eight sessions of individual family 
versus group family psychoeducation therapy, Geist et al35 
found no differences on any self-report measures of eat-
ing disorder symptoms or noneating disorder pathology. 
Lastly, in a relatively large family therapy trial, Lock et al36 
examined the effectiveness of short (10 sessions over six 
months) versus long-term (20 sessions over one year) family 
therapy. This study found no differences between the groups 
for eating disorder, mood or anxiety symptoms, suggesting 
that the majority of adolescents with AN may benefit from 
short-term family therapy. However, results indicated that 
individuals with more severe obsessions and compulsions 
related to   eating or those with nonintact families did signifi-
cantly better in the long term compared with the short-term 
treatment group. Thus, identification of specific factors 
associated with the eating disorder may be important mark-
ers in determining the type of treatment most beneficial for 
a given individual.
Adherence
Adherence to family therapy in adolescents with AN has been 
high, with treatment completion rates ranging from 81% to 
100% across studies. In the study conducted by Eisler et al33 
comparing two forms of family therapy, the majority of 
patients remained in the study for a full year (n = 29, 73%) 
with another seven participants completing more than three 
months of treatment. Adherence to family therapy has also 
been high in adults, with completion rates ranging from 76% 
to 93%.28,30,37
Safety
Overall, two studies reported patients needing to be admitted 
(or readmitted) to an inpatient program during the family ther-
apy treatment trial.35,36 In the first study,35 five of 25 patients 
(20%) receiving either individual or group family therapy 
needed to be readmitted to the hospital, although they all 
still completed the trial. Similar rates of hospitalization were 
found in a treatment trial comparing short-term versus long-
term family therapy, with 19 of 86 patients (22%) requiring 
hospitalization (average 18 days) due to medical instability.36 
There were no differences in need for hospitalization between 
the two treatment groups, and participants re-entered their 
original treatment condition after hospital discharge.
Other psychotherapy
In addition to family therapy and CBT, other forms of 
behavioral, cognitive, and psychodynamic   psychotherapies, 
  including educational behavioral therapy (EBT),   cognitive 
analytic therapy, cognitive orientation therapy, self-  psychology, 
and focal psychoanalytic psychotherapy, have been studied 
in individuals with AN. As previously mentioned, behavioral 
therapies for AN are based on the explanatory model that 
dysfunctional behavioral patterns are the maintaining factors 
of the disorder. Thus, EBT entailed monitoring daily intake, 
with the overall goal of increasing the amount and variety of 
food consumed. In contrast, current psychodynamic thera-
pies for AN are largely based on attachment theory and the 
explanatory model that dysfunctional eating patterns provide 
a sense of security for AN patients. Cognitive analytic therapy 
(CAT) follows a psychodynamic framework focusing not 
only on self-monitoring of behaviors but also interpersonal 
and transference issues. Whereas CAT combines elements 
of cognitive, behavioral, and psychodynamic therapies, focal 
psychodynamic psychotherapy focuses on the conscious and 
unconscious meanings of the eating disorder symptoms and 
how these symptoms influence current relationships.37 Self-
psychology also is a psychoanalytic therapy with the viewpoint 
that patients with AN cannot rely on themselves to fulfill their 
self needs, and thus must rely on either the avoidance or con-
sumption of food to fulfill such needs.38
Efficacy
Treasure et al39 compared outpatient EBT with CAT in 
adults with AN. At one-year follow-up, results indicated 
that individuals in the CAT group had significantly 
greater self-reported improvements, but no other dif-
ferences between the groups were found. Bachar et al38 
reported that self-psychology was superior to cognitive 
orientation therapy in an RCT limited by a small sample 
size (n = 13) and high rate of drop-out (67%) in the cog-
nitive orientation group. Finally, to evaluate further the 
use of individual psychodynamic treatments and family 
therapy in adults with AN, Dare et al37 randomized 84 
patients with AN (one male) to one of four groups, ie, 
one year of focal psychoanalytic psychotherapy, seven 
months of CAT, one year of family therapy, or one year 
of low-contact “routine” treatment. In terms of weight 
gain, those in the three treatment groups had greater 
improvements compared with those in the routine 
group. More specifically, individuals in the focal psy-
choanalytic or family therapy group had significantly 
greater weight gain compared with the routine group at Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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one-year follow-up. However, despite improvements in 
the psychotherapy groups, more than two-thirds of the 
patients remained underweight at one-year follow-up. 
Furthermore, although the treatment groups fared better 
than routine treatment, it was not possible to differentiate 
improvements among groups.
Adherence
As previously mentioned, adolescent treatment com-
pliance for cognitive orientation therapy was poor (33%). 
Adult compliance for EBT (63%) and CAT (71%) was 
good and did not differ significantly between groups. In 
the study conducted by Dare et al37 patients were signifi-
cantly more likely to remain in one of the psychotherapy 
treatment groups compared with the routine treatment 
group.
Safety
No patients receiving either EBT or CAT required inpatient 
treatment.39 In contrast, two patients (9%) receiving CAT 
required hospitalization during the course of   treatment.37 
Hospitalization also was required for two (11%) patients in 
the focal psychoanalytic group, three (14%) in the   family 
therapy group, and five (26%) in the routine treatment 
group.37 Additionally, one patient in the routine treatment 
group died during the study. Overall, patients were signifi-
cantly less likely to remain as an outpatient in the routine 
treatment compared with the three specialized treatments, 
suggesting improved medical safety associated with CAT, 
family therapy, and focal psychoanalytic therapy compared 
with treatment as usual.37
Hospitalization and intensive 
multidisciplinary approaches
Given the medical risks associated with symptoms of AN 
and increased risk of a fatal outcome,3 inpatient and day 
hospitalization are widely used treatments for AN, and 
are often considered the surest ways to achieve weight 
gain in this population, given the ability to provide a con-
trolled environment. However, only two RCTs have been 
conducted comparing inpatient hospitalization with other 
forms of treatment.40,41 Both inpatient and day programs 
are   intensive multidisciplinary approaches generally com-
prised of specific behavioral refeeding programs with the 
end goals of medical stability and normalization of weight 
and eating patterns. Although hospitalization programs are 
often effective in normalizing weight in patients with AN, 
relapse rates remain high.
Efficacy
In the first RCT of hospitalization, Crisp et al40 compared 
the effectiveness of inpatient treatment with two forms of 
outpatient psychotherapy and a dietary counseling control 
group in late adolescents with AN. The treatment groups 
comprised: inpatient treatment followed by 12 sessions of 
outpatient individual and family psychotherapy; outpatient 
individual and family psychotherapy with dietary counseling; 
and outpatient group psychotherapy, with groups for both 
the patients and parents. At one-year follow-up, individuals 
in the two outpatient treatment groups gained significantly 
more weight than those in the dietary counseling control 
group, but they did not differ from each other or from the 
inpatient group. The second RCT was conducted in a group 
of 167 adolescents with AN who were randomized to inpa-
tient treatment, specialized outpatient treatment, or general 
child and adolescent mental health outpatient services.41 In 
intent-to-treat analyses at two-year follow-up, there were 
no significant differences between the groups in terms of 
Morgan–Russell outcomes,29 eating disorder symptoms, 
clinician-rated severity, depression, or family functioning.
Adherence
Crisp et al40 observed greater refusal to engage in treatment 
when randomized to inpatient treatment. Similarly, Gowers 
et al41 found significant variability in adherence to treatment 
allocation among conditions, with inpatients   having the 
lowest rate of adherence (49.1%) compared with both the 
specialized (74.5%) and generalized outpatient (69.1%) 
treatments. Although inpatient settings allow for more con-
trol over adherence to treatment protocols than outpatient 
settings, during voluntary hospitalization patients have the 
ability to leave treatment against medical advice. In general, 
reported drop-out rates for inpatient treatment have ranged 
from 20% to 50% and from 13% to 19% for day hospital 
treatments,42 suggesting that the latter may represent a more 
acceptable form of treatment.
Safety
Gowers et al41 reported that 31 of 110 individuals (28%) 
assigned to the two outpatient programs required hospital 
admission within the year. In general, individuals with AN 
who are in need of hospitalization tend to be more severe and 
are at risk for several medical complications including gas-
trointestinal, endocrine, neurologic, renal, and cardiovascular 
problems. Although hospitalization and refeeding programs 
are necessary to diminish many of these life-threatening 
complications, in some significantly malnourished patients, Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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refeeding syndrome can develop in the beginning stages 
of nutritional rehabilitation. Refeeding syndrome is a mul-
tifaceted metabolic complication that can be fatal if not 
treated properly. Physician monitoring of serum potassium, 
phosphates, and magnesium, as well as the development of 
edema and vital signs is imperative, especially during early 
stages of refeeding.43 Neither RCT reported having patients 
with refeeding syndrome or severe medical complications,40,41 
and no reliable estimates of this rare, but potentially fatal, 
complication have been provided in the literature.
Discussion
Overall, results from RCTs suggest that few treatments 
are adequately effective in the treatment of AN. No 
  pharmacologic agent has emerged as a treatment of choice 
for AN. Unlike TCAs, SSRIs seem to be well tolerated, with 
low rates of adverse events or serious side effects, but there 
has been a failure to replicate an early finding that SSRIs 
might prevent relapse in weight-restored patients. Moreover, 
controlled trials do not support the use of antidepressants to 
improve weight gain, ED symptomatology, or associated 
psychopathology in underweight or weight-restored patients 
with AN. Preliminary evidence suggests that olanzapine may 
be beneficial in facilitating weight gain and appears to be 
well tolerated by patients. Thus, replication in larger samples 
where safety and adherence can be better assessed represents 
an important direction for future research.
No single psychological treatment has demonstrated clear 
superiority over other psychological treatments in adults with 
AN, not only in terms of efficacy but also in terms of patient 
adherence to the therapy and safety (ie, need for hospitaliza-
tion). Both behavioral therapy and CBT appear effective in 
treating some symptoms of AN compared with nutritional 
counseling control conditions. However, CBT has not dem-
onstrated greater efficacy compared with other psychological 
interventions. In contrast, family therapy in adolescents with 
AN has demonstrated efficacy compared with alternative 
psychotherapies in two independent RCTs, resulting in its 
recognition as a well established psychosocial intervention 
using the American Psychological Association’s Task Force 
criteria.44 Several RCTs suggest that various forms of family 
therapy are effective in treating adolescents, with good rates 
of adherence for up to one year of treatment.
Overall, results highlight the difficulty in treating 
individuals with AN, and further emphasize the importance of 
continued efforts in developing new treatments. Thus far, treat-
ment studies with AN have been confronted almost universally 
with small sample sizes due to both the low base rate of the 
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disorder and its ego-syntonic nature. The   disorder is relatively 
rare, affecting 0.5% of females in their lifetime,1 and many 
patients endorse lack of motivation for treatment.45
One study evaluated factors leading to nonacceptance 
and noncompletion in three treatment conditions (medica-
tion, CBT, and combination of medication and CBT) within 
a multisite RCT.45 Overall, 46% of patients dropped out, 
with greater treatment acceptance in the CBT and combined 
treatment groups (81%) compared with the medication 
alone treatment group (56%).45 This finding suggests that 
despite any potential benefits associated with olanzapine, 
treatment with medication alone may not be acceptable to 
nearly half of patients with AN.45 Among those in the CBT 
or combined treatment groups, individuals with high obses-
sive   preoccupations had greater acceptance (91%) compared 
with those who had low obsessive preoccupations (52%). 
Furthermore, the only predictor of treatment completion 
among the treatment acceptors was high self-esteem. Taken 
together, these findings highlight the need to improve accep-
tance and to reduce drop-out, especially in individuals with 
low self-esteem and fewer obsessive preoccupations.
In addition to low point prevalence and low motivation to 
engage in treatment, medical complications provoked by AN 
contribute to discontinuation in outpatient treatment studies. 
This discontinuation further contributes to small sample 
sizes, particularly when there are concerns about random-
izing severely ill patients to an outpatient treatment condi-
tion. The severity of this disorder limits use of no treatment 
or placebo only comparison groups due to ethical concerns. 
The lack of no-treatment comparison conditions eliminates 
the opportunity to identify treatments as “probably effica-
cious” according to the American Psychological Associa-
tion’s Task Force criteria, and the lack of placebo comparison 
groups eliminates one route to developing well established 
treatments according to these criteria.46 Thus, when trials find 
no significant differences among different active treatments, 
it is unclear whether both treatments are effective but neither 
is superior or whether neither is effective.
In response to challenges faced when conducting RCTs 
in AN, researchers are actively pursuing novel approaches 
for the treatment of AN, particularly in late adolescent 
and adult populations, for which no psychosocial treat-
ment of choice has been identified.47 A recent Request for 
  Applications from the National Institutes of Mental Health 
targeted the development of innovative treatments for AN, 
yielding funding for four treatment trials currently under 
way. These trials include an examination of couple-based 
therapy in adults,48 cognitive remediation therapy (CRT),49 
emotional acceptance behavior therapy,50 and food expo-
sure therapy and ritual response prevention (AN-EX/RP).51 
Each therapy is informed by interventions that have proven 
effective in other mental disorders, as well as an enhanced 
understanding of the vulnerabilities that contribute to the 
development of AN.
Couple-based therapy is a CBT intervention targeting 
core symptoms of AN as well as the unique challenges the 
disorder places on couples. This therapy can be conceived 
of as an extension of family-based therapies for children 
and adolescents with AN to the meaningful family unit in 
adults with AN. CRT is designed to address specific cogni-
tive impairments found in AN, and it has been found to be 
effective for teaching cognitive skills in other disorders (eg, 
schizophrenia, obsessive-compulsive disorder). In the current 
trial, CRT   followed by CBT will be compared with CBT alone. 
While CRT focuses on improving cognitive skills, emotional 
acceptance behavior therapy emphasizes behavioral principles 
and strategies to attempt to increase emotional awareness 
and decrease avoidance of emotional negative states. Lastly, 
AN-EX/RP uses cognitive and behavioral techniques to 
address anxiety and avoidance behaviors surrounding meals 
specifically. In the current pilot study, six months of outpa-
tient AN-EX/RP will be compared with CBT in a group of 
weight-restored patients with AN to   examine the effective-
ness of AN-EX/RP in reducing food avoidance and relapse. 
This treatment is based on an explanatory model in which 
AN is a fear-based disorder similar to anxiety disorders with 
which AN shares high levels of comorbidity52 and familial 
transmission.53
In addition to these four innovative treatment trials, 
several other treatment studies are currently under way 
in both adolescents and adults with AN. Using the search 
term “anorexia nervosa” in the World Health Organization 
  International Clinical Trials Research Platform and the 
National Institutes of Health clinicaltrials.gov databases 
yielded 24 RCTs, with 10 having anticipated sample sizes 
of greater than 60 participants per treatment arm. In terms of 
medication, a large multisite outpatient RCT of olanzapine 
versus placebo is under way in adults with AN.54 Ongoing 
psychotherapy   trials include further exploration of CBT 
and family therapy, as well as other forms of psychotherapy 
in the treatment of AN. CBT is being compared with focal 
  psychodynamic55 and CBT-based activity therapy56 in 
RCTs with sample sizes of more than 200 patients. Behav-
ioral   family therapy is being compared with individual 
ego-oriented therapy,57 family systems therapy,58 and family 
systems or individual therapy59 in adolescents, and with Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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specialist supportive clinical   management in adults with 
AN.60 A large trial with a target sample of 400 patients is 
comparing inpatient treatment, multifamily day treatment, 
and outpatient family therapy in adolescents with AN.61 
Treatment setting is also being explored in a trial, comparing 
the effectiveness of 12-week inpatient versus day hospitaliza-
tion for adolescents with AN across six hospitals.62 Lastly, 
one large (n = 180) Internet-based relapse prevention trial is 
testing an Internet program against treatment as usual fol-
lowing inpatient therapy.63 Thus, although published studies 
to date have been plagued by small sample sizes, there are 
many ongoing trials that are attempting to improve on this 
limitation. Given the diversity of approaches being employed, 
the future may provide greater insights into the efficacious 
treatment of AN.
In the pursuit of evidence-based treatments for AN, 
future research should examine moderators and mediators 
of   treatment effects. Moderators are factors not related to 
the treatment condition, but identify potential subgroups 
for which treatment effects may be more or less powerful. 
For example, Lock et al36 found severity of obsessions and 
compulsions and nonintact families to be associated with 
greater improvements in the long term compared with 
short-term family therapy. Mediators explain how or why a 
given effect occurs. For example, if food exposure therapy 
and ritual response prevention contributes to lower anxiety 
around food and eating, and lower anxiety around food 
and eating contributes to weight gain, then the mechanism 
(reduced anxiety) would be understood for this intervention. 
Examination of both moderators and mediators can help 
identify which treatments may work best for whom and under 
what circumstances, and may in turn help increase rates of 
compliance and reduce rates of drop-out.
In conclusion, evidence for treatments in AN remains 
limited despite decades of RCTs, and there are no definitive 
treatments that work best for the majority of patients. For 
adolescent patients, family-based therapy represents a well 
established treatment according to the American Psychologi-
cal Association’s Task Force criteria46 but was not accepted as 
a Grade A treatment according to the National Institute for 
Clinical Excellence guidelines (ie, at least one RCT as part 
of a body of literature of overall good quality and consistency 
addressing the specific recommendation without extrapola-
tion).47 Because future research is under way, it is imperative 
to continue to put forth effort to increase adherence and 
motivation for treatment in those with AN in order to conduct 
trials with a greater number of individuals and help patients 
derive all potential benefits from a given treatment.
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